BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Oncology Today - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oncology Today
X-ORIGINAL-URL:https://oncologynewstoday.co.uk
X-WR-CALDESC:Events for Oncology Today
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250617T123000
DTEND;TZID=Europe/London:20250617T133000
DTSTAMP:20250429T084409Z
CREATED:20250429T084409Z
LAST-MODIFIED:20250429T084409Z
UID:7345-1750163400-1750167000@oncologynewstoday.co.uk
SUMMARY:FREE WEBINAR: Selecting doublet vs triple therapy in metastatic hormone-sensitive prostate cancer
DESCRIPTION:Tue 17 Jun 2025 12:30 PM – 1:30 PM BST  \n Online\, Zoom \nSpeaker: Prof. Giuseppe Luigi Banna \nShort abstract:\nThis presentation explores systemic therapy options for metastatic hormone-sensitive prostate cancer (mHSPC)\, emphasizing the comparative efficacy and safety of doublet versus triplet regimens. It reviews key clinical trials\, highlighting outcomes like overall survival and progression-free survival across diverse patient populations. The discussion includes considerations for treatment personalization based on disease volume and genomic biomarkers. Emerging imaging modalities and their impact on staging are also addressed\, along with insights into future therapeutic strategies leveraging biomarker-driven approaches. \nEducational outcomes – 3 points: \n1. Improved Survival with Systemic Therapy Intensification: Clinical trials have demonstrated significant survival benefits from intensifying systemic therapy in mHSPC. Both doublet and triplet regimens\, incorporating androgen deprivation therapy (ADT) with agents like docetaxel\, darolutamide\, abiraterone\, apalutamide or enzalutamide\, have shown enhanced overall survival and progression-free survival\, especially in high-volume disease settings. \n2. Role of Advanced Imaging in Staging: Next-generation imaging modalities\, such as PSMA PET/CT and whole-body MRI\, have led to stage migration by detecting metastases more accurately than conventional imaging methods. This improved staging impacts treatment decisions and may refine the identification of patients suitable for systemic or metastasis-directed therapies. \n3. Personalised Treatment Strategies: Emerging approaches focus on tailoring therapy based on genomic biomarkers (e.g.\, BRCA mutations\, PTEN loss) and patient characteristics like frailty or disease volume. These strategies aim to optimize treatment efficacy while minimizing toxicity\, particularly in older or vulnerable populations.
URL:https://oncologynewstoday.co.uk/event/free-webinar-selecting-doublet-vs-triple-therapy-in-metastatic-hormone-sensitive-prostate-cancer/
LOCATION:Oncology News Today
CATEGORIES:Oncology Events
END:VEVENT
END:VCALENDAR